DE69730839T2 - Hühner polynukleotide impfstoff-formulierung - Google Patents

Hühner polynukleotide impfstoff-formulierung Download PDF

Info

Publication number
DE69730839T2
DE69730839T2 DE69730839T DE69730839T DE69730839T2 DE 69730839 T2 DE69730839 T2 DE 69730839T2 DE 69730839 T DE69730839 T DE 69730839T DE 69730839 T DE69730839 T DE 69730839T DE 69730839 T2 DE69730839 T2 DE 69730839T2
Authority
DE
Germany
Prior art keywords
vaccine
plasmid
virus
gene
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69730839T
Other languages
German (de)
English (en)
Other versions
DE69730839D1 (de
Inventor
Jean-Christophe Audonnet
Annabelle Bouchardon
Michel Riviere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health France SAS
Original Assignee
Merial SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial SAS filed Critical Merial SAS
Publication of DE69730839D1 publication Critical patent/DE69730839D1/de
Application granted granted Critical
Publication of DE69730839T2 publication Critical patent/DE69730839T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/255—Marek's disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/22011—Dicistroviridae
    • C12N2770/22034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE69730839T 1996-07-19 1997-07-16 Hühner polynukleotide impfstoff-formulierung Expired - Lifetime DE69730839T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9609339A FR2751225B1 (fr) 1996-07-19 1996-07-19 Formule de vaccin polynucleotidique aviaire
FR9609339 1996-07-19
PCT/FR1997/001326 WO1998003659A1 (fr) 1996-07-19 1997-07-16 Formule de vaccin polynucleotidique aviaire

Publications (2)

Publication Number Publication Date
DE69730839D1 DE69730839D1 (de) 2004-10-28
DE69730839T2 true DE69730839T2 (de) 2005-09-29

Family

ID=9494451

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69730839T Expired - Lifetime DE69730839T2 (de) 1996-07-19 1997-07-16 Hühner polynukleotide impfstoff-formulierung

Country Status (19)

Country Link
US (3) US6221362B1 (enExample)
EP (2) EP1523992A1 (enExample)
JP (2) JP2001503019A (enExample)
KR (1) KR20000065258A (enExample)
CN (2) CN1701788A (enExample)
AR (1) AR013063A1 (enExample)
AU (1) AU735184B2 (enExample)
BR (1) BR9710495A (enExample)
CA (1) CA2261343A1 (enExample)
CO (1) CO4700304A1 (enExample)
DE (1) DE69730839T2 (enExample)
ES (1) ES2232876T3 (enExample)
FR (1) FR2751225B1 (enExample)
HU (1) HU224830B1 (enExample)
ID (1) ID19475A (enExample)
MA (1) MA24268A1 (enExample)
NZ (1) NZ333779A (enExample)
TN (1) TNSN97120A1 (enExample)
WO (1) WO1998003659A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751225B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
ZA978434B (en) * 1996-09-27 1998-03-26 Akzo Nobel Nv Inactivated vaccines.
US6468984B1 (en) * 1999-06-08 2002-10-22 Innovo Biotechnologies Ltd. DNA vaccine for protecting an avian against infectious bursal disease virus
WO2000077218A1 (en) * 1999-06-10 2000-12-21 Agricultural Research Council Vaccine for newcastle disease virus
AR031405A1 (es) * 2000-11-21 2003-09-24 Wyeth Corp Metodos y vacunas para conferir proteccion in ovo contra la rinotraqueitis del pavo
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
US7615209B2 (en) 2001-09-12 2009-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions of NDV and methods of use thereof for treatment of cancer
IL145397A0 (en) * 2001-09-12 2002-06-30 Yissum Res Dev Co Compositions and methods for treatment of cancer
US7037506B2 (en) * 2002-03-08 2006-05-02 Schweltzer Chemical Corporation Ltd. Vaccine accelerator factor (VAF) for improvement of vaccinations in poultry
US7029681B2 (en) * 2002-03-08 2006-04-18 Schweitzer Chemical Corporation Multiple and multivalent DNA vaccines in ovo
EP1494708A1 (en) * 2002-04-12 2005-01-12 Capua, Ilaria Purified subfragment codifying for neuroaminidase, recombinant neuroaminidase and its use in zooprophylaxis
KR101123023B1 (ko) * 2002-10-15 2012-03-15 와이어쓰 엘엘씨 조류 조직 샘플중의 바이러스 검출 분석 방법
EP2390352A1 (en) 2003-03-18 2011-11-30 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
EP1689858B1 (en) 2003-11-13 2013-05-15 University Of Georgia Research Foundation, Inc. Methods of characterizing infectious bursal disease virus
MXPA06009452A (es) 2004-02-19 2007-03-15 Univ Alberta Polimorfismos del promotor de leptin y sus usos.
SI1881845T1 (sl) 2005-04-25 2010-06-30 Merial Ltd Cepiva proti virusu Nipah
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
DE102005040812A1 (de) * 2005-08-27 2007-03-15 Few Fahrzeugelektrikwerk Gmbh & Co. Kg Elektrischer Anschluss sowie Verfahren zu dessen Verbindung mit der Scheibe eines Kraftfahrzeugs
EP1951751B1 (en) 2005-11-14 2017-11-01 Merial, Inc. Gene therapy for renal failure
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
US20080274137A1 (en) * 2007-05-02 2008-11-06 Jean Christophe Francis Audonnet DNA plasmids having improved expression and stability
KR101445903B1 (ko) 2007-05-02 2014-09-29 메리얼 리미티드 향상된 발현 및 안정성을 갖는 ｄｎａ 플라스미드
JP5578073B2 (ja) * 2008-06-03 2014-08-27 旭硝子株式会社 コア−シェル粒子の製造方法および中空粒子の製造方法
MX2011005604A (es) 2008-11-28 2011-09-01 Merial Ltd Vacuna recombinante para influenza aviar y sus usos.
JP5797636B2 (ja) 2009-04-03 2015-10-21 メリアル リミテッド ニューカッスル病ウイルスをベクターとするトリワクチン
WO2011090708A2 (en) 2009-12-28 2011-07-28 Merial Limited Recombinant ndv antigen and uses thereof
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
US9345759B2 (en) 2010-03-12 2016-05-24 Merial, Inc. Bluetongue virus recombinant vaccines and uses thereof
JP5913316B2 (ja) 2010-08-31 2016-04-27 メリアル リミテッド ニューカッスル病ウイルスをベクターとするヘルペスウイルスワクチン
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
AU2012240246A1 (en) 2011-04-04 2013-05-09 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
EP2694677A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
KR102007444B1 (ko) 2011-04-25 2019-08-06 어드밴스드 바이오사이언스 라보라토리즈, 인코포레이티드 절단형 hiv 피막 단백질(env), 이와 관련된 방법 및 조성물
NZ618125A (en) 2011-05-27 2016-03-31 Merial Ltd Genetic vaccines against hendra virus and nipah virus
ES2674439T3 (es) 2011-06-01 2018-06-29 Merial, Inc. Administración sin aguja de vacunas contra el VSRRP
US10166188B2 (en) 2011-08-12 2019-01-01 Merial, Inc. Method for vacuum-assisted preservation of biologics including vaccines
JP6149301B2 (ja) * 2011-11-30 2017-06-21 メリアル インコーポレイテッド トリ病原体の抗原を発現する組換えガリドヘルペスウイルス３（ｍｄｖ血清型２）ベクター及びその使用
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
US9567606B2 (en) 2012-02-14 2017-02-14 Merial Inc. Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom
JP6149240B2 (ja) 2012-02-14 2017-06-21 メリアル インコーポレイテッド ロタウイルスサブユニットワクチン並びにその製造及び使用方法
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
CA2876196C (en) 2012-06-13 2021-09-21 Merial Limited Reassortant btv vaccines
CN102719567A (zh) * 2012-07-05 2012-10-10 广东温氏食品集团有限公司 禽传染性支气管炎病毒h120毒株的pcr检测引物及检测方法
HK1216006A1 (zh) 2013-03-12 2016-10-07 Boehringer Ingelheim Animal Health USA Inc. 反向遺傳學施馬倫貝格病毒疫苗組合物，和其使用方法
EP3395169A1 (en) 2014-05-19 2018-10-31 Merial Inc. Method and device for conditional in ovo injection
IL241841B (en) * 2014-09-30 2019-09-26 Univ Free State Production of proteins for human and animal health using yarrowia lipolytica
US10010499B2 (en) 2014-11-03 2018-07-03 Merial Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
CN104881148B (zh) * 2015-05-15 2017-12-15 苏州达方电子有限公司 键盘及其控制方法
WO2016210094A1 (en) 2015-06-23 2016-12-29 Merial, Inc. Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
EP3337503A1 (en) 2015-08-20 2018-06-27 Merial, Inc. Fcv recombinant vaccines and uses thereof
AR106026A1 (es) 2015-09-29 2017-12-06 Merial Inc Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos
KR102153303B1 (ko) 2015-11-23 2020-09-09 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 Fmdv 및 e2 융합 단백질 및 이의 용도
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
CN107099513B (zh) * 2017-06-22 2020-07-14 北京邦卓生物科技有限公司 一种共表达ndv hn和ibdv vp2基因的hvt的构建及其应用
JP7276776B2 (ja) 2018-01-26 2023-05-18 全国農業協同組合連合会 非ヒト動物用抗原表面結合型リポソームワクチン
CN110777122A (zh) * 2019-10-21 2020-02-11 青岛易邦生物工程有限公司 一种表达ibdv的vp2蛋白的重组ⅰ型马立克氏病病毒
CN115089700B (zh) * 2022-05-25 2025-07-25 永州中古生物技术有限公司 一种抗β属冠状病毒的疫苗组合物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0474676A4 (en) * 1989-05-30 1993-02-24 The Commonwealth Scientific And Industrial Research Organization Production of ibdv vp2 in highly immunogenic form
JPH06509235A (ja) * 1991-07-26 1994-10-20 ヴァイロジェネティクス　コーポレイション 伝染性ファブリキウス嚢病ウイルス組換えポックスウイルスワクチン
FR2697534A1 (fr) * 1992-11-02 1994-05-06 Rhone Merieux Virus herpès de la dinde recombinant pour la réalisation de vaccin de la maladie de Gumboro, son procédé de préparation et vaccin obtenu.
EP0620277A1 (en) * 1993-03-18 1994-10-19 Merck & Co. Inc. Nucleic acid pharmaceuticals
EP1650310A1 (en) * 1993-04-14 2006-04-26 Commonwealth Scientific And Industrial Research Organisation Recombinant avian adenovirus vector
DE69536091D1 (de) * 1994-01-27 2010-09-09 Univ Massachusetts Medical Immunisierung durch Impfung von DNS Transkriptionseinheit
JPH08116976A (ja) * 1994-10-20 1996-05-14 Chemo Sero Therapeut Res Inst 免疫用核酸調製物およびこれを用いた免疫方法
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
FR2728794B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
WO1996021034A1 (fr) * 1994-12-30 1996-07-11 Rhone Merieux Vaccin vivant recombinant aviaire
FR2751225B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
US5916879A (en) 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
US6468984B1 (en) * 1999-06-08 2002-10-22 Innovo Biotechnologies Ltd. DNA vaccine for protecting an avian against infectious bursal disease virus

Also Published As

Publication number Publication date
MA24268A1 (fr) 1998-04-01
US20020037292A1 (en) 2002-03-28
CN1225685A (zh) 1999-08-11
JP2001503019A (ja) 2001-03-06
CO4700304A1 (es) 1998-12-29
WO1998003659A1 (fr) 1998-01-29
CN1701788A (zh) 2005-11-30
FR2751225B1 (fr) 1998-11-27
DE69730839D1 (de) 2004-10-28
BR9710495A (pt) 1999-08-17
AU3773697A (en) 1998-02-10
EP0914442A1 (fr) 1999-05-12
ID19475A (id) 1998-07-16
HU224830B1 (en) 2006-02-28
CA2261343A1 (fr) 1998-01-29
KR20000065258A (ko) 2000-11-06
AU735184B2 (en) 2001-07-05
US6464984B2 (en) 2002-10-15
HUP9902790A2 (hu) 1999-12-28
NZ333779A (en) 2000-07-28
JP2009149608A (ja) 2009-07-09
TNSN97120A1 (fr) 2005-03-15
US20030124145A1 (en) 2003-07-03
ES2232876T3 (es) 2005-06-01
AR013063A1 (es) 2000-12-13
HUP9902790A3 (en) 2000-03-28
EP0914442B1 (fr) 2004-09-22
FR2751225A1 (fr) 1998-01-23
US6221362B1 (en) 2001-04-24
EP1523992A1 (fr) 2005-04-20

Similar Documents

Publication Publication Date Title
DE69730839T2 (de) Hühner polynukleotide impfstoff-formulierung
DE69734778T2 (de) Polynukleotid-impfstoffformulierung gegen pferdekrankheiten
DE69731309T3 (de) Impfstofformel auf polynukleotidbasis zur behandlung von hundekrankheiten, insbesondere solcher des atmungs- und verdauungstraktes
DE69725988T2 (de) Polynukleotid-impfstoff, vorzugsweise zur behandlung der atemkrankheit bei rindern
DE69734284T2 (de) Zusammensetzung eines polynukleotidvakzins zur behandlung von atemwegs- und fortpflanzungsbezogenen erkrankungen des schweins
DE69736185T2 (de) Zusammensetzung eines polynucleotid-impfstoffes für katzen
DE69532068T2 (de) Rekombinanter lebender Vogel-Impfstoff, der ein Truthahn-Herpesvirus Vektor gebraucht
DE69715879T2 (de) Intradermaler polynukleotid-impfstoff aus rind
AT408549B (de) Virushältiger impfstoff, rekombinantes virus und verfahren zum exprimieren eines genproduktes
DE3856141T2 (de) Respiratorisches syncytiales virus, impstoffe
DE69632235T2 (de) Newcastle-Krankheitsvirus-Kombinationsimpfstoff
DE69837390T2 (de) Rekombinanter schweine adenovirus vektor
DE60219865T2 (de) Auf Herpesvirus gegründeter rekombinanter Impfstoff gegen die infektiöse Bursalkrankheit
DE69935136T2 (de) DNS Pferdeimpfstoffe adjuviert mit Acryl- oder Methacrylpolymersäuren oder EMA (R)
DE69737231T2 (de) Impfung mit nukleinsäuren gegen parvovirus infektionen
DE69533305T2 (de) Lebende rekombinante Vogelvakzine auf eines Vogelherpesvirus gegründet, gegen Gumborokrankheit
DE68920610T2 (de) Rekombinantes Virus der Marekschen Krankheit und Vakzin.
DE69233270T2 (de) Subeinheits-Impfstoff gegen Hundecoronavirus
DE69123970T2 (de) Ehv-4 glykoprotein vazin
DE69929530T2 (de) Attenuierter pferdeherpesvirus
DE69935445T2 (de) Attenuierte stabile tollwutvirusmutante und lebende impfstoffe
DE69627109T2 (de) REKOMBINANTES HERPESVIRUS UNTER DER VERWENDUNG DES gB GENPROMOTERS
DE60208854T2 (de) Attenuierte rekombinante stabile Tollwutvirusmutanten und Lebendimpfstoffe
DE60222528T2 (de) Impfstoff gegen Pferdearteritisvirus
AU2004210602B2 (en) Avian polynucleotide vaccine formula

Legal Events

Date Code Title Description
8364 No opposition during term of opposition